logo-loader

Chimeric Therapeutics granted European patent for cancer-fighting asset CHM 1101

Published: 14:01 23 Sep 2021 AEST

Chimeric Therapeutics Ltd - Chimeric Therapeutics granted European patent for cancer-fighting asset CHM 1101

Chimeric Therapeutics Ltd (ASX:CHM) has gained European patent protection for its cancer-fighting, clinical-stage CAR T asset, CHM 1101.

The patent covers certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including CHM 1101, with patent protection expected until 2036.

This patent, granted by the European Patent Office under the technical name of EP 3,362,470 B1, means Chimeric holds the exclusive worldwide licence to develop and commercialise CHM 1101.

The news has brought a positive response from investors with shares up as much as 12.7% to A$0.355.

Another step forward

Chimeric CEO and managing director Jennifer Chow said the patent protection would hold the company in good stead as it pushed on with its clinical trial program.

“We are pleased to see the continued advancement of the strong intellectual property portfolio underpinning Chimeric’s CLTX CAR T program, on this occasion in a geography that holds significant market potential,” she said.

CHM 1101, a novel CAR T cell therapy that uniquely utilises Chlorotoxin as its tumour targeting domain, has shown promising pre-clinical safety and efficacy and is being studied in a single site phase-I clinical trial.

CLTX CAR T trial

The company’s CLTX CAR T recently reached a key safety milestone with all patients dosed in the first patient cohort, with the phase 1 clinical trial progressing beyond the 28-day follow up period without experiencing dose-limiting toxicities.

Achievement of this safety milestone enables the trial to progress to the second dosing level, which will introduce dual CLTX CAR T administration (ICT administration and intracranial intraventricular (ICV) administration) at a dose of 88 X 106 CAR T cells. This will also enable patient dosing without a mandated stagger.

Beneficial partnership

Chimeric also signed a strategic partnership deal with OncoBay Clinical to provide comprehensive research support to advance and expand the clinical development program for CHM 1101.

OncoBay Clinical, a subsidiary of the Moffitt Cancer Center, is a boutique clinical research organisation (CRO) that has extensive experience in cell therapy development.

Chow said: “OncoBay is a natural partner for us, building upon the cell therapy expertise of our team.

“With its experience managing the complexity of cell therapy research programs and scientific support from the Moffitt Cancer Center, we believe that the team at OncoBay is uniquely positioned to support the expansion of the CHM 1101 (CLTX CAR T) development program."

- Daniel Paproth

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

3 hours, 31 minutes ago